Mark
Punyanitya

Most founders pitch a slide. He pitches a vehicle.

Ask Mark Punyanitya to describe the future and he does not reach for a deck. He reaches for a road. Picture an MRI scanner riding in the back of a truck, he says, bumping toward a village that has never had one. That single image - a hospital-grade machine where you would least expect it - is the whole argument behind PhenoMx, the company he co-founded and runs as President and CEO from New York.

The premise is almost rude in its simplicity. Medical imaging has spent decades locked in the basements of academic hospitals, expensive and stationary and quietly out of reach for most of the planet. Punyanitya's plan is to pick the lock. "Take medical imaging, which traditionally has been quite behind-the-scenes," he says, "essentially liberate it, have an opportunity to use it anytime, anywhere."

He is a biomedical engineer by training, with graduate work in applied physiology and applied clinical trials, and the unglamorous distinction of having read other people's scans for a living long before he tried to read everyone's. That order matters. He learned the hard part first.

Before the startup, there was the slice.

Long before "quantified self" became a phrase you could buy a wristband for, Punyanitya was doing the literal version inside a research lab. He came up through the Obesity Research Center at St. Luke's-Roosevelt Hospital and the Institute of Human Nutrition, tied to Columbia University, where body composition was studied the slow way: cross-section by cross-section, measuring tissue from MRI and CT with a rigor most people never see.

That work turned into a back catalog of more than forty-four peer-reviewed papers and a reputation for one specific, valuable skill - turning a fuzzy medical image into a hard number that a clinical trial can trust. He spent over fifteen years standardizing MRI, CT and DEXA scans for academic, pharmaceutical, and government studies. It is the kind of resume that does not photograph well and matters enormously.

Out of that came the Image Reading Center, the company he founded and still leads - an imaging core laboratory and contract research organization that builds imaging biomarkers for global, multi-center trials. In plain terms: when a drug company runs a study across dozens of hospitals, someone has to make sure a scan in Tokyo means the same thing as a scan in Texas. That someone is often him.

A scan is just a picture until someone turns it into a number.

Here is the part of the job that never makes the brochure. A medical image is, at first, just light and shadow. To be useful in a clinical trial it has to become a measurement - a hard, repeatable figure that holds steady whether the scanner sits in one country or another, whether the technician is having a good day or a bad one. That translation, from picture to number, is the entire discipline Punyanitya spent his career mastering.

It is called imaging biomarker development, and it is unforgiving work. Standardize the protocol. Calibrate the machines. Control for every variable that could make the same body look different twice. Do it across dozens of sites at once. The reward for getting it right is invisible: a study that can actually trust its own eyes. The penalty for getting it wrong is a result nobody can believe.

This is why his startup pitch is so credible. PhenoMx is not the idea of a man who read about imaging. It is the idea of someone who has already solved the hardest version of the problem - reproducibility at scale - and now wants to package that solved problem and ship it. The automation he keeps describing is, in a sense, his own expertise written down so the machine can carry it instead of him.

The pitch, in his own words.

He has a habit of making a very technical thing sound almost obvious. The "Pitch & Partner" session is the clearest place to hear the argument land - the village, the truck, the five-minute scan, all of it.

It is worth noting how rarely he talks about the machine itself. The story is always about who gets to stand in front of it.

Closing a gap, one scan at a time.

For all the talk of radiomics, phenotyping and precision medicine, Punyanitya keeps circling back to a stubbornly human goal. The fancy capability is not the prize. The reach is. "Whether that's in a large city, a small village, or even a rural environment," he says - the sentence trails off because the list is meant to be endless.

His phrasing for the mission is unfussy: "making the gap between the health disparities much closer together." It is the same instinct that sent a researcher into the unglamorous corners of body composition science in the first place. Measure carefully. Then make the measurement available to people who never had it.

There is a quiet provocation in the way he frames precision medicine, too. He named a whole conference roundtable after the doubt: is it actually that precise? Coming from one of the field's own biomarker engineers, that is not cynicism. It is a builder refusing to let his own industry coast on a buzzword.

It also explains why he gravitates toward the language of the quantified self and human longevity rather than the language of the clinic. The vision is a body you can measure as casually as you check the weather - a personalized, repeatable snapshot rather than a once-a-decade event. The difference between those two worlds is mostly a matter of cost and access, which is exactly the seam he keeps trying to pry open. Drive the price down, shrink the time to five minutes, automate the expertise, and the rare becomes routine.